Pre-Open Movers 5/27: Chemtura (CEM) Up on Takeover Reports, Favrille (FVRL) Sinks After Drug Fails - Street Insider

Sign Up | Log In | What is SocialPicks?

Pre-Open Movers 5/27: Chemtura (CEM) Up on Takeover Reports, Favrille (FVRL) Sinks After Drug Fails
May 27, 2008 01:16 PM UTC

Street Insider

Return	Risk
+0.33%	MID

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
CEM	n/a
FVRL	n/a
SPF	n/a

Via StreetInsider.com News Articles:

StreetInsider.com Pre-Open Movers:

Favrille, Inc. (Nasdaq: FVRL) 78% LOWER; announced results from the Company's Phase 3 registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma. Analysis of time to progression, the primary endpoint in the trial, failed to show a statistically significant improvement in the treatment arm, Specifid plus Leukine following Rituxan, compared to the control arm, placebo plus Leukine following Rituxan. Analysis of all subgroups also did not show any significant differences in primary or secondary endpoints when adjusted for prognostic factors.

Standard Pacific Corp. (NYSE: SPF) 23.8% HIGHER; has entered into a definitive agreement

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.